Skip to main content
UKPMC Funders Author Manuscripts logoLink to UKPMC Funders Author Manuscripts
. Author manuscript; available in PMC: 2016 Jan 4.
Published in final edited form as: Org Lett. 2014 May 19;16(11):2954–2957. doi: 10.1021/ol501093v

Streocontrolled Construction of Six Vicinal Stereogenic Centers on Spiropyrazolones via Organocascade Michael/Michael/1,2-Addition Reactions

Pankaj Chauhan 1, Suruchi Mahajan 1, Charles C J Loh 1, Gerhard Raabe 1, Dieter Enders 1,*
PMCID: PMC4699267  EMSID: EMS66352  PMID: 24840166

Abstract

A highly stereoselective one-pot procedure for the synthesis of spiropyrazolone derivatives bearing six contiguous stereogenic centers including two tetrasubstituted carbons has been developed. Under sequential catalysis by two organocatalysts, a cinchona-derived aminosquaramide and DBU, a series of diversely functionalized spiropyrazolones are obtained in good yields (47–62%) and excellent stereoselectivities (up to >25:1 dr and 98–99% ee). The opposite enantiomers of the spiropyrazolones are also accessible by employing a pseudoenantiomeric aminosquaramide catalyst.

Graphical Abstract

graphic file with name emss-66352-f0001.jpg


The synthesis of pyrazolone derivatives has attracted considerable attention in recent years due to their wide spectrum of applications in dye, analytical, and pharmaceutical chemistry.1,2 Edaravone (A), a neuroprotective agent, and metamizole (B), an effective analgesic and antipyretic agent, are two important pharmaceutically valuable pyrazolones (Figure 1).1c–f In addition to these, the pyrazolone derivatives such as C exhibit HIV inhibition activity.1g Recently, the pyrazolones were found to be inhibitors of the CD80 protein and also possess potent activity in inhibiting protease-resistant prion protein accumulation, cytokines, and p38 kinases.1h–k Pyrazol-3-one derivatives have also been studied as multidrug resistance modulators.1l

Figure 1.

Figure 1

Biologically active pyrazolone derivatives.

On the other hand, spirocyclic frameworks frequently found in many synthetic bioactive compounds and natural products fascinated many researchers to develop synthetic strategies for their construction. Because of their complex three-dimensional structure, the stereoselective synthesis of spirocyclic molecules from simple precursors in an atom-economic fashion is considered as a tough challenge.3 Recently, the organocatalytic cascade/domino reactions emerged as an efficient strategy to provide such complex structures in an operationally simple one-pot procedure,4 and we have witnessed tremendous growth in the asymmetric synthesis of spirocyclic oxindole derivatives especially employing organocascade sequences.5 Despite the many important applications of the pyrazolone moiety, the catalytic asymmetric synthesis of spiropyrazolones is less explored.

The Rios group reported the asymmetric synthesis of spiropyrazolones bearing three contagious stereogenic centers via a secondary amine catalyzed domino reaction (Scheme 1).6 Rios and co-workers were also able to construct four stereocenters on a spiropyrazolones in a three-component domino reaction.7 The cinchona-derived primary amines were found to catalyze the domino Michael/Michael reaction of the enones with the pyrazolones8 and the unsaturated pyrazolones9 to afford the spirocyclohexanonepyrazolones with three consecutive stereogenic centers. Recently, spiropyrazolones bearing an N-heterocyclic ring with three adjacent stereogenic centers were synthesized by aminothioureas10 and quinine11 catalyzed domino Michael/cyclization reactions.

Scheme 1. Catalytic Enantioselective Strategies for the Synthesis of Spiropyrazolone Derivatives.

Scheme 1

To the best of our knowledge, the asymmetric synthesis of spirocyclohexanepyrazolones bearing more than four stereocenters are not known. We took up this challenge and developed a one-pot protocol for the asymmetric synthesis of the spiropyrazolones bearing as many as six stereogenic centers including two adjacent tetrasubstituted ones. It was envisaged that an organocascade sequence involving a stereoselective Michael/Michael/1–2-addition reaction between β-dicarbonyl compounds 1, nitroalkenes 2, and unsaturated pyrazolones 3 mediated by sequential organocatalysis12 using a chiral bifunctional organocatalyst13 and an achiral base could afford such highly functionalized spiropyrazolones (Scheme 1).

To attain our objective at the onset, we performed a one-pot reaction that involved a quinine-derived squaramide (1 mol %) catalyzed Michael addition of ethyl acetoacetate (1a) to (E)-β-nitrostyrene (2a) in dichloromethane. After 24 h, the unsaturated pyrazolone 3a and a guanidine base TBD (20 mol %) in dichloromethane were added sequentially. To our delight, the desired spiropyrazolone bearing four tertiary and two tetrasubstituted stereogenic centers was obtained in a good yield of 41% and excellent enantio- (99% ee) and diastereoselectivity (>25:1 dr) (Table 1, entry 1). The screening of other achiral bases (entries 2–6) showed that the DBU provides the best yield as well as excellent stereoselectivity (entry 2). The screening of solvents such as chloroform, toluene, and THF did not result in any improvement in the product yield (entries 7–9). Further efforts for optimizing the yield of 4a by increasing the catalyst loading of DBU revealed that with 50 mol % DBU a better yield was observed; however, a further increase in the amount of DBU did not show any improvement in the product yield. Using 2 equiv of 3 the spiropyrazolone 4 was isolated in maximum yield of 60% with excellent stereoselectivity (entries 13 and 14).

Table 1. Optimization of the Reaction Conditions for the Asymmetric Synthesis of the Spiropyrazolone 4aa.

graphic file with name emss-66352-t0006.jpg

entry base (x mol %) solvent yieldb (%) eec (%)
1 TBD (20) CH2Cl2 41 99
2 DBU (20) CH2Cl2 44 99
3 DBN (20) CH2Cl2 43 99
4 DABCO (20) CH2Cl2 12 99
5d piperidine (20) CH2Cl2 14 98
6d pyrrolidine (20) CH2Cl2 12 98
7 DBU (20) CHCl3 35 99
8 DBU (20) toluene 34 99
9 DBU (20) THF 35 99
10 DBU (30) CH2Cl2 46 99
11 DBU (50) CH2Cl2 52 99
12e DBU (100) CH2Cl2 36 99
13f DBU (30) CH2Cl2 57 99
14f DBU (50) CH2Cl2 60 99
a

Reaction conditions: 0.2 mmol of 1a, 0.2 mmol of 2a, 1 mol % of I, 0.24 mmol of 3a, and x mol % of base (0.1 M in solvent).

b

Yield of isolated 4a after flash column chromatography.

c

Enantiomeric excess of the major diastereomer (>25:1 dr) determined by HPLC analysis on a chiral stationary phase.

d

The reaction was run for 96 h in the second step.

e

The reaction was run for 0.5 h in the second step.

f

0.40 mmol of 3a was used.

Armed with optimized conditions, we further evaluated the substrate scope on a 0.5 mmol scale (Table 2). Various pyrazolone-derived olefins bearing electron-withdrawing and electron-releasing substituents at the different aromatic position reacted efficiently under the standard reaction conditions to afford the desired spiropyrazolones 4b–i in good yields and excellent enantio- and diastereoselectivities (entries 2–9). The heteroaromatic pyrazolone derivative was also tolerated under this one-pot organocascade procedure, thus resulting in the desired spiropyrazolone 4j in 55% yield with excellent ee (entry 10). The unsaturated pyrazolone bearing an o-chlorophenyl group gives 47% yield of product 4k with 99% ee (entry 11).

Table 2. Substrate Scope of the Asymmetric Synthesis of Spiropyrazolones 4 with Catalyst Ia.

graphic file with name emss-66352-t0007.jpg

entry R1 R2 R3 R4 4 yieldb (%) eec (%)
1 OEt Ph Ph Ph 4a 62 99
2 OEt Ph 4-ClC6H4 Ph 4b 58 99
3 OEt Ph 4-BrC6H4 Ph 4c 62 99
4 OEt Ph 4-CF3C6H4 Ph 4d 61 99
5 OEt Ph 3-ClC6H4 Ph 4e 60 99
6 OEt Ph 4-MeC6H4 Ph 4f 52 99
7 OEt Ph 4-MeOC6H4 Ph 4g 57 99
8 OEt Ph 2-MeC6H4 Ph 4h 55 99
9 OEt Ph 3-MeOC6H4 Ph 4i 57 99
10 OEt Ph 2-thienyl Ph 4j 55 99
11 OEt Ph Ph 2-ClC6H4 4k 47 99
12 OEt 4-FC6H4 Ph Ph 4l 57 99
13 OEt 4-ClC6H4 Ph Ph 4m 58 99
14 OEt 4-MeC6H4 Ph Ph 4n 56 98
15 OEt 4-MeOC6H4 Ph Ph 4o 56 99
16d OEt 2-furanyl Ph Ph 4p 55 99
17 OEt 2-thienyl Ph Ph 4q 59 99
18 OMe Ph Ph Ph 4r 57 99
19 Me Ph Ph Ph 4s 53 99
a

Reaction conditions: 0.5 mmol of 1, 0.5 mmol of 2, 1 mol % of I, 1.0 mmol of 3, and 50 mol % of DBU (0.1 M in CH2Cl2).

b

Yield of the isolated product after flash column chromatography.

c

Enantiomeric excess of the major diastereomer (>25:1 dr).

d

12:1 dr.

Different aromatic nitroalkenes bearing electron-withdrawing as well as electron-donating substituents also allowed an efficient access to the spiropyrazolones 4l–o in good yield and excellent ee of 98–99% (entries 12–15). The nitroalkenes bearing heteroaromatic groups also provide the desired adducts 4p and 4q in good yields and excellent stereoselectivities (entries 16 and 17). We also tried other dicarbonyl compounds such as methyl acetoacetate and acetylacetone, which efficiently reacted under this one-pot protocol to afford the adducts 4r and 4s in 57% and 53% yield and 99% ee (entries 18 and 19).

After generating two tetrasubstituted adjacent carbon atoms on the spiropyrazolone, we tried to create three consecutive tetrasubstituted carbons by employing a trisubstituted β-ketoester. A one-pot organocatalytic sequence promoted by I and DBU between the β-ketoester 5, (E)-β-nitrostyrene (2a), and pyrazolone 3a provided the spiropyrazolone 6 bearing three contiguous tertiary and three tetrasubstituted stereogenic centers in excellent stereoselectivity (>25:1 dr and 95% ee), albeit in a low yield of 16% (Scheme 2).

Scheme 2. Asymmetric Synthesis of Spiropyrazolone with Three Contiguous Tetrasubstituted Stereocenters.

Scheme 2

The absolute configuration of the spiropyrazolones 4a–s could be assigned as (1R), (2S), (3S), (4S), (5S), and (6R) based on the X-ray structure of 4c.14

We have also tested the catalytic potential of aminosquaramide catalyst II derived from quinidine in place of catalyst I to generate the opposite enantiomer of the corresponding product. With catalyst II, various spiropyrazolone derivatives were accessible in good yields and excellent enantio- and diastereoselectivities (Table 3).

Table 3. Substrate Scope of the Asymmetric Synthesis of Spiropyrazolones ent-4 with Catalyst IIa.

graphic file with name emss-66352-t0008.jpg

entry R1 R2 R3 ent-4 yieldb (%) eec (%)
1 OEt Ph Ph ent-4a 61 99
2 OEt Ph 4-ClC6H4 ent-4b 57 97
3 OEt Ph 3-ClC6H4 ent-4e 60 98
4 OEt Ph 4-MeC6H4 ent-4f 50 98
5 OEt Ph 3-MeOC6H4 ent-4i 57 98
6 OEt 4-FC6H4 Ph ent-4l 60 97
7 OEt 4-ClC6H4 Ph ent-4m 57 98
8 OEt 4-MeC6H4 Ph ent-4n 56 97
9d OEt 2-thienyl Ph ent-4q 61 98
10 OMe Ph Ph ent-4r 59 98
a

Reaction conditions: 0.5 mmol of 1, 0.5 mmol of 2, 1 mol % of II, 1.0 mmol of 3, and 50 mol % of DBU (0.1 M in CH2Cl2).

b

Yield of the isolated product after flash column chromatography.

c

Enantiomeric excess of the major diastereomer (>25:1 dr).

d

10:1 dr.

In order to demonstrate the practical utility of this one-pot protocol, we have performed a gram-scale cascade Michael/Michael/1,2-addition reaction between 1a, 2a, and 3a using a lower loading (0.5 mol %) of catalyst I (Scheme 3). The desired spiropyrazolone 4a was obtained in 59% yield without deteriorating the stereochemical outcome of the reaction.

Scheme 3. Gram-Scale One-Pot Stereoselective Synthesis of Spiropyrazolone 4a.

Scheme 3

In conclusion, we have disclosed a one-pot procedure for the synthesis of a new series of potentially biologically important spiropyrazolone derivatives. A variety of spirocyclohexanepyrazolone derivatives bearing six stereocenters including two vicinal tetrasubstituted carbons were obtained in good yields and excellent stereoselectivities via sequential organocatalytic Michael/Michael/1,2-addition reactions facilitated by a low loading of a cinchona-derived amino squaramide and a readily available achiral base. This one-pot cascade sequence can be scaled up without losing the reaction efficiency in terms of product yield and stereoselectivity. The opposite enantiomer of the spiropyrazolones can be also synthesized in good yield and excellent stereoselectivity by employing a pseudoenantiomeric catalyst.

Supplementary Material

546_Enders_Chauhan_OrgLett_supp

ACKNOWLEDGMENTS

Support from the European Research Council (ERC Advanced Grant “DOMINOCAT”) is gratefully acknowledged.

Footnotes

Supporting Information

Experimental details and full spectroscopic data for all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

Notes

The authors declare no competing financial interest.

REFERENCES

  • (1).For a book on pyrazolone chemistry, see: ; (a) Varvounis G. Pyrazol-3-ones. Part IV: Synthesis and Applications. In: Katritzky AR, editor. Advances in Heterocyclic Chemistry. Vol. 98. Academic Press; New York: 2009. p. 143. [Google Scholar]; For reviews, see: ; (b) Horton DA, Bourne GT, Smythe ML. Chem. Rev. 2003;103:893. doi: 10.1021/cr020033s. [DOI] [PubMed] [Google Scholar]; (c) Watanabe T, Tanaka K, Watanabe K, Takamatsu Y, Tobe A. Yakugaku Zasshi. 2004;124:99. doi: 10.1248/yakushi.124.99. [DOI] [PubMed] [Google Scholar]; (d) Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N. CNS Drug Rev. 2006;12:9. doi: 10.1111/j.1527-3458.2006.00009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]; For selected examples, see: ; (e) Hinz B, Cheremina O, Bachmakov J, Renner B, Zolk O, Fromm MF, Brune K. FASEB J. 2007;21:2343. doi: 10.1096/fj.06-8061com. [DOI] [PubMed] [Google Scholar]; (f) Wong A, Sibbald A, Ferrero F, Plager M, Santolaya ME, Escobar AM, Campos S, Barragan S, Gonzalez MDL, Kesselring GLF. Clin. Pediatr. 2001;40:313. doi: 10.1177/000992280104000602. [DOI] [PubMed] [Google Scholar]; (g) Hadi V, Koh Y-H, Sanchez TW, Barrios D, Neamati N, Jung KW. Bioorg. Med. Chem. Lett. 2010;20:6854. doi: 10.1016/j.bmcl.2010.08.057. [DOI] [PMC free article] [PubMed] [Google Scholar]; (h) Uvebrant K, Thrige DDG, Rosén A, Åkesson M, Berg H, Walse B, Björk P. J. Biomol. Screen. 2007;12:464. doi: 10.1177/1087057107300464. [DOI] [PubMed] [Google Scholar]; (i) Kimata A, Nakagawa H, Ohyama R, Fukuuchi T, Ohta S, Suzuki T, Miyata N. J. Med. Chem. 2007;50:5053. doi: 10.1021/jm070688r. [DOI] [PubMed] [Google Scholar]; (j) Golebiowski A, Townes JA, Laufersweiler MJ, Brugel TA, Clark MP, Clark CM, Jane FD, Laughlin SK, Sabat MP, Bookland RG, VanRens JC, De B, Hsieh LC, Janusz MJ, Walter RL, Webster ME, Mekel MJ. Bioorg. Med. Chem. Lett. 2005;15:2285. doi: 10.1016/j.bmcl.2005.03.007. [DOI] [PubMed] [Google Scholar]; (k) Clark MP, Laughlin SK, Laufersweiler MJ, Bookland RG, Brugel TA, Golebiowski A, Sabat MP, Townes JA, VanRens JC, Djung JF, Natchus MG, De B, Hsieh LC, Xu SC, Walter RL, Mekel MJ, Heitmeyer SA, Brown KK, Juergens K, Taiwo YO, Janusz MJ. J. Med. Chem. 2004;47:2724. doi: 10.1021/jm049968m. [DOI] [PubMed] [Google Scholar]; (l) Wang XH, Wang XK, Liang YJ, Shi Z, Zhang JY, Chen LM, Fu LW. Chin. J. Cancer. 2010;29:980. doi: 10.5732/cjc.010.10309. [DOI] [PubMed] [Google Scholar]
  • (2).For recent examples of the construction of pyrazolone derivatives, see: ; (a) Gogoi S, Zhao C-G. Tetrahedron Lett. 2009;50:2252. doi: 10.1016/j.tetlet.2009.02.210. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Gogoi S, Zhao C-G, Ding D. Org. Lett. 2009;11:2249. doi: 10.1021/ol900538q. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Mariappan G, Saha BP, Bhuyan NR, Bharti PR, Kumar DJ. Adv. Pharm. Technol. Res. 2010;1:260. [PMC free article] [PubMed] [Google Scholar]; (d) Ma R, Zhu J, Liu J, Chen L, Shen X, Jiang H, Li J. Molecules. 2010;15:3593. doi: 10.3390/molecules15053593. [DOI] [PMC free article] [PubMed] [Google Scholar]; (e) Liao Y-H, Chen W-B, Wu Z-J, Du X-L, Cun L-F, Zhang X-M, Yuan W-C. Adv. Synth. Catal. 2010;352:827. [Google Scholar]; (f) Yang Z, Wang Z, Bai S, Liu X, Lin L, Feng X. Org. Lett. 2011;13:596. doi: 10.1021/ol102804p. [DOI] [PubMed] [Google Scholar]; (g) Mazzanti A, Calbet T, Font-Bardia M, Moyano A, Rios R. Org. Biomol. Chem. 2012;10:1645. doi: 10.1039/c2ob06553c. [DOI] [PubMed] [Google Scholar]; (h) Šimek M, Remeš M, Veselý J, Rios R. Asian J. Org. Chem. 2013;2:64. [Google Scholar]
  • (3).For recent reviews on the stereoselective synthesis of spirocyclic compounds, see: ; (a) Trost BM, Brennan MK. Synthesis. 2009:3003. [Google Scholar]; (b) Rios R. Chem. Soc. Rev. 2012;41:1060. doi: 10.1039/c1cs15156h. [DOI] [PubMed] [Google Scholar]; (c) Nakazakia A, Kobayashi S. Synlett. 2012:1427. [Google Scholar]; (d) Franz AK, Hanhan NV, Ball-Jones NR. ACS Catal. 2013;3:540. [Google Scholar]
  • (4).For selected reviews on organocatalytic domino/cascade reactions, see: ; (a) Enders D, Grondal C, Hűttl MRM. Angew. Chem., Int. Ed. 2007;46:1570. doi: 10.1002/anie.200603129. [DOI] [PubMed] [Google Scholar]; (b) Yu X, Wang W. Org. Biomol. Chem. 2008;6:2037. doi: 10.1039/b800245m. [DOI] [PubMed] [Google Scholar]; (c) Grondal C, Jeanty M, Enders D. Nat. Chem. 2010;2:167. doi: 10.1038/nchem.539. [DOI] [PubMed] [Google Scholar]; (d) Albrecht Ł, Jiang H, Jørgensen KA. Angew. Chem., Int. Ed. 2011;50:8492. doi: 10.1002/anie.201102522. [DOI] [PubMed] [Google Scholar]; (e) Moyano A, Rios R. Chem. Rev. 2011;111:4703. doi: 10.1021/cr100348t. [DOI] [PubMed] [Google Scholar]; (f) Grossmann A, Enders D. Angew. Chem., Int. Ed. 2012;51:314. doi: 10.1002/anie.201105415. [DOI] [PubMed] [Google Scholar]; (g) Pellissier H. Adv. Synth. Catal. 2012;354:237. [Google Scholar]; (h) Loh CCJ, Enders D. Chem.—Eur. J. 2012;18:10212. doi: 10.1002/chem.201200287. [DOI] [PubMed] [Google Scholar]; (i) Lu L-Q, Chen J-R, Xiao W-J. Acc. Chem. Res. 2012;45:1278. doi: 10.1021/ar200338s. [DOI] [PubMed] [Google Scholar]; (j) Volla CMR, Atodiresei I, Rueping M. Chem. Rev. 2014;114:2390. doi: 10.1021/cr400215u. [DOI] [PubMed] [Google Scholar]; For recent highlights, see: ; (k) Chauhan P, Enders D. Angew. Chem., Int. Ed. 2014;53:1485. doi: 10.1002/anie.201309952. [DOI] [PubMed] [Google Scholar]
  • (5).For recent reviews on the organocatalytic asymmetric synthesis of spirooxindoles, see: ; (a) Zhou F, Liu Y-L, Zhou J. Adv. Synth. Catal. 2010;352:1381. [Google Scholar]; (b) Badillo JJ, Hanhan NV, Franz AK. Curr. Opin. Drug Discovery Dev. 2010;13:758. [PubMed] [Google Scholar]; (c) Dalpozzo R, Bartoli G, Bencivenni G. Chem. Soc. Rev. 2012;41:7247. doi: 10.1039/c2cs35100e. [DOI] [PubMed] [Google Scholar]; (d) Ball-Jones NR, Badillo JJ, Franz AK. Org. Biomol. Chem. 2012;10:5165. doi: 10.1039/c2ob25184a. [DOI] [PubMed] [Google Scholar]; (e) Hong L, Wang R. Adv. Synth. Catal. 2013;355:1023. [Google Scholar]; (f) Liu Y, Wang H, Wan J. Asian J. Org. Chem. 2013;2:374. doi: 10.1002/ajoc.201200184. [DOI] [PMC free article] [PubMed] [Google Scholar]; (g) Chauhan P, Chimni SS. Tetrahedron: Asymmetry. 2013;24:343. [Google Scholar]; (h) Cheng D, Ishihara Y, Tan B, Barbas CF., III ACS Catal. 2014;4:743. [Google Scholar]
  • (6).(a) Companyó X, Zea A, Alba A-NR, Mazzanti A, Moyano A, Rios R. Chem. Commun. 2010;46:6953. doi: 10.1039/c0cc01522a. [DOI] [PubMed] [Google Scholar]; (b) Alba A-NR, Zea A, Valero G, Calbet T, Font-Bardía M, Mazzanti A, Moyano A, Rios R. Eur. J. Org. Chem. 2011;7:1318. [Google Scholar]
  • (7).Zea A, Alba A-NR, Mazzanti A, Moyano A, Rios R. Org. Biomol. Chem. 2011;9:6519. doi: 10.1039/c1ob05753g. [DOI] [PubMed] [Google Scholar]
  • (8).Wu B, Chen J, Li M-Q, Zhang J-X, Xu X-P, Ji SJ, Wang X-W. Eur. J. Org. Chem. 2012:1318. [Google Scholar]
  • (9).(a) Liang J, Chen Q, Liu L, Jiang X, Wang R. Org. Biomol. Chem. 2013;11:1441. doi: 10.1039/c2ob27095a. [DOI] [PubMed] [Google Scholar]; (b) Zhang J-X, Li NK, Liu Z-M, Huang XF, Geng Z-C, Wang X-W. Adv. Synth. Catal. 2013;355:797. [Google Scholar]
  • (10).Liu L, Zhong Y, Zhang P, Jiang X, Wang R. J. Org. Chem. 2012;77:10228. doi: 10.1021/jo301851a. [DOI] [PubMed] [Google Scholar]; (b) Chen Q, Liang J, Wang S, Wang D, Wang R. Chem. Commun. 2013;49:1657. doi: 10.1039/c3cc38386e. [DOI] [PubMed] [Google Scholar]
  • (11).Cui BD, Li S-W, Zuo J, Wu ZJ, Zhang X-M, Yuan W-C. Tetrahedron. 2014;70:1895. [Google Scholar]
  • (12).For recent examples on organocatalytic sequential one-pot reactions, see: ; (a) Jiang K, Jia Z-J, Chen S, Wu L, Chen Y-C. Chem.—Eur. J. 2010;16:2852. doi: 10.1002/chem.200903009. [DOI] [PubMed] [Google Scholar]; (b) Enders D, Urbanietz G, Cassens-Sasse E, Keeß S, Raabe G. Adv. Synth. Catal. 2012;354:1481. [Google Scholar]; (c) Hong B-C, Dange NS, Ding C-F, Liao J-H. Org. Lett. 2012;14:448. doi: 10.1021/ol202877m. [DOI] [PubMed] [Google Scholar]; (d) Dange NS, Hong B-C, Lee C-C, Lee G-H. Org. Lett. 2013;15:3914. doi: 10.1021/ol4016749. [DOI] [PubMed] [Google Scholar]; (e) Li X, Yang L, Peng C, Xie X, Leng H-J, Wang B, Tang Z-W, He G, Ouyang l., Huang W, Han B. Chem. Commun. 2013:8692. doi: 10.1039/c3cc44004d. [DOI] [PubMed] [Google Scholar]
  • (13).For selected reviews on the bifunctional hydrogen bonding organocatalysis, see: ; (a) Doyle AG, Jacobsen EN. Chem. Rev. 2007;107:5713. doi: 10.1021/cr068373r. [DOI] [PubMed] [Google Scholar]; (b) Bhadury PS, Song B-A, Yang S, Hu D-Y, Xue W. Curr. Org. Synth. 2009;6:380. [Google Scholar]; (c) Siau WY, Wang J. Catal. Sci. Technol. 2011;1:1298. [Google Scholar]; (d) Alemán J, Parra A, Jiang H, Jørgensen KA. Chem.—Eur. J. 2011;17:6890. doi: 10.1002/chem.201003694. [DOI] [PubMed] [Google Scholar]; (e) Chauhan P, Chimni SS. RSC Adv. 2012;2:737. [Google Scholar]
  • (14).CCDC 997149 (for 4c) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. For X-ray structure, see Supporting Information.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

546_Enders_Chauhan_OrgLett_supp

RESOURCES